变性高效液相色谱法检测CpG岛胞嘧啶甲基化

目的 建立一种新型的ＣpＧ岛胞嘧啶甲基化快速检测方法。方法 用亚硫酸氢钠处理ＤＮＡ,丙用链特异性聚合酶链反应（ＰＣＲ）对错配修复基因hＭＬＨ１启动子含ＣpＧ位点的靶序列进行扩增;利用变性高效液相色谱法（ＤＨＰＬＣ）在部分变性温度下测定靶序列的保留时间,并与亚硫酸氢钠－酶切法测定结果进行比较。结果 用ＤＨＰＬＣ对结肠癌细胞株ＲＫＯ和胃癌细胞株ＰＡＣＭ８２的hＭＬＨ１启动子进行测定,发现ＲＫＯ细胞ＰＣＲ产物的保留时间显长于ＰＡＣＭ８２细胞ＰＣＲ产物的保留时间（６．７min比６．２min）。ＲＫＯ细胞ＰＣＲ产物保留时间的延长是亚硫酸氢钠处理后的模板中胞嘧啶和鸟嘌呤含量较ＰＡＣＭ８２高所致。从此结果分析,可以判断出ＲＫＯ的hＭＬＨ１启动子已甲基化,而ＰＡＣＭ８２细胞未甲基化。此结果与酶切法结果完全一致。结论 新方法可以快速检测ＣpＧ岛胞嘧啶甲基化。     

Blue toe syndrome: treatment with percutaneous atherectomy

"Blue toe syndrome" refers to digital ischemia of the foot in the presence of palpable or Doppler audible pedal pulses. This clinical syndrome is caused by microembolization to small vessels from a proximal source. The use of percutaneous transluminal atherectomy is described in the treatment of embologenic superficial femoral artery lesions in seven patients. All seven had prompt healing of the ischemic toes, and none required surgical revascularization or amputation. One patient developed a recurrent stenosis at the atherectomy site and had a second episode of digital ischemia, which was treated by means of atherectomy with a larger device. Histologic study of atherectomy specimens suggests that emboli arise from adherent fibrinoplatelet aggregates or thrombus and less often from cholesterol-rich atheromatous plaque. Although either percutaneous transluminal angioplasty or atherectomy can be used to treat the underlying stenosis, percutaneous atherectomy offers the advantage of nonsurgical removal of embologenic material and provides material for histologic study. Percutaneous atherectomy is an effective method of treating embologenic superficial femoral stenoses in patients with ipsilateral blue toe syndrome.     

卵清白蛋白特异性T细胞免疫诱导BALB/c小鼠的调节性免疫应答

目的：研究T细胞免疫后正常小鼠的调节性免疫应答，方法：应用体外扩增的卵清白蛋白（OVA）特异的T细胞克隆免疫BALB／c小鼠，3H－TdR掺入法分析细胞增殖，3H－TdR标记靶细胞检测杀伤T细胞的杀伤效应，间接免疫荧光法分析血清中抗T细胞抗体水平。结果：T细胞免疫后能诱导BALB/c小鼠产生调节性T细胞的增殖反应，对靶细胞的杀伤效应以及针对于活化的T细胞的体液免疫应答，并进一步降低机体对OVA抗原的应答，结论：T细胞免疫能诱导正常机体的调节性免疫应答。     

经鼻内镜筛窦纸板进路眶内手术

目的探讨经鼻内镜筛窦纸板进路手术治疗眶内各种疾病的可行性并确立临床处理的基本原则.方法经鼻内镜进路眶内手术10例眶内异物取出术4例、球后海绵状血管瘤切除术1例、眶内侵犯或转移的恶性肿瘤切除术5例.结果眶内异物取出术3例成功,1例失败;球后海绵状血管瘤1例完整切除;鼻咽癌眶内转移1例手术切除+放射治疗后随访4年无复发,视力恢复至0.6;其他眶内恶性肿瘤4例,手术后随访1～4年均健在.10例手术后1例视力损伤,9例均保留原有视力,其中3例失明病例中2例视力有一定程度的恢复.结论位于视神经内侧的某些占位性病变可以经鼻内镜筛窦纸板进路完成.当代先进的放射治疗技术为眶内恶性肿瘤的保守性手术创造了条件.     

替拉万星(telavancin):一种新型脂糖肽类抗菌药

替拉万星(telavancin,TD-6424)是万古霉素的衍生物,用于治疗耐药革兰阳性菌,特别是MRSA感染。本文对替拉万星作用机制、抗菌活性、药动学、药效学、临床适应证和不良事件等作一简要介绍。一、作用机制     

Stratum corneum lipids liposomes for the topical delivery of 5-aminolevulinic acid in photodynamic therapy of skin cancer: preparation and in vitro permeation study

Background  

Photodynamic therapy (PDT) using 5-aminolevulinic acid (5-ALA) is a skin cancer therapy that still has limitations due to the low penetration of this drug into the skin. We have proposed in this work a delivery system for 5-ALA based on liposomes having lipid composition similar to the mammalian stratum corneum (SCLLs) in order to optimize its skin delivery in Photodynamic Therapy (PDT) of skin cancers.